FSD Stock Recent News

Tesla, Inc.'s Q4 2024 results missed expectations, but future growth prospects in FSD, AI, and robotics make it one of my top long ideas for 2025. Despite lower automotive margins, Tesla's energy and services segments showed strong growth, with the new Model Y expected to boost ASPs and margins. Exciting developments include FSD rollouts, robotaxi services, and the Optimus robot, potentially driving significant revenue and profitability growth in the coming years.

@LikeFolio's Andy Swan argues Tesla (TSLA) is one of the best stocks on the market. While he notes criticism around Elon Musk's ambitions, he argues the quality of Tesla products has and will continue to improve as it focuses on A.I.

Elon Musk recently touted Tesla (TSLA -2.78%) FSD's "exponential improvement" based on data from a crowd-sourced site. But is that really what's being shown?

-Jobless claims at an eight-week low -Tesla plans full self driving launch in China and Europe -Nippon Steel's US Steel bid faces Biden barrier Manus Cranny reports. Tune into "Bloomberg Brief" at 5 a.m.

Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the proposed consolidation of its issued and outstanding class A multiple voting shares ("Class A Multiple Voting Shares") and class B subordinate voting shares ("Class B Subordinate Voting Shares") of the Company on the basis of one (1) post-consolidation Class A Multiple Voting Share and Class B Subordinate Voting Share for every sixty-five (65) pre-consolidation Class A Multiple Voting Shares and Class B Subordinate Voting Shares (the "Consolidation"). This ratio is within the ratio range approved by the Company's stockholders at its annual general and special meeting held on July 22, 2024.

FSD Pharma (NASDAQ: HUGE ) stock is taking off on Friday after the biopharmaceutical company provided investors with an update on its investment in Celly Nutrition . FSD Pharma notes that Celly Nutrition is closing in on the launch of its “unbuzzd” product.

TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption. On August 9, 2024, Celly Nutrition which is backed by a world-class pharmaceutical research & development team at FSD Pharma, operated by CEO John Duffy, formerly of Coca-Cola, and co-chaired by Gerry David the former CEO of Celsius Holdings (CELH) proudly announces the imminent launch of its revolutionary, great tasting and scientifically backed product, unbuzzd™.

Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9). FSD Pharma (NASDAQ: HUGE) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10481/217645_fsdpharmalogo.jpg To read the full article on 247marketnews.com, please click here.

Denver, Colorado--(Newsfile Corp. - July 23, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting small cap market biotech developments, featuring FSD Pharma (NASDAQ: HUGE). FSD Pharma (NASDAQ: HUGE) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10481/217432_2c52394c544c9bc9_logo_lg.jpg To read the full article on 247marketnews.com, please click here The report discusses FSD Pharma's revolutionary rapid alcohol detoxification drink, UNBUZZD™, which helps to rapidly restore mental alertness post-alcohol consumption.

This article discusses the upcoming merger of First Trust High Income Long/Short Fund into abrdn Income Credit Strategies Fund. The merger of FSD into ACP was approved, with shares to de-list on July 19, 2024. FSD shareholders to receive NAV for NAV shares in ACP, which is trading at a premium to NAV.